This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haden, S. T. Articles by El-Hajj Fuleihan, G. Search for Related Content PubMed PubMed Citation Articles by Haden, S. T. Articles by El-Hajj Fuleihan, G.

Alterations in Parathyroid Dynamics in Lithium-Treated Subjects¹

Endocrine-Hypertension Division (S.T.H., S.M., J.S., G.E.-H.F.) and Psychiatry Division (A.L.S.), Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115

Address all correspondence and requests for reprints to: Ghada El-Hajj Fuleihan, M.D., M.P.H., Endocrine-Hypertension Division, Brigham and Women’s Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, Massachusetts 02115. E-mail: gelhajjful{at}bics.bwh.harvard.edu

Chronic lithium (Li) therapy, used extensively in the treatment of bipolar affective disorders, is one of psychiatry’s most effective treatments. The data on the effects of Li on baseline PTH and calcium (Ca) levels are conflicting. A clear resetting of the PTH set-point to the right was documented in vitro; however, the effect of Li on the Ca-PTH axis has not been rigorously studied in vivo. In this study, we used a Ca and citrate infusion protocol to fully characterize PTH dynamics in seven female patients, 40 ± 11 yr old, on chronic Li therapy for 5.23 ± 4.0 yr, compared with seven controls, 41 ± 16 yr old (mean ± SD). Baseline ionized Ca (Ca_i) and intact PTH levels were 5.2 ± 0.06 mg/dL and 38.4 ± 5.7 pg/mL in the Li group and 4.9 ± 0.06 mg/dL and 21.2 ± 5.0 pg/mL in the controls, (mean ± SEM) P = 0.008 and 0.042, respectively. We defined an inverse sigmoidal curve between Ca_i and the intact biologically active PTH molecule (iPTH) for the two study groups and demonstrated a significant shift in the iPTH set-point to the right in the Li-treated patients, compared with controls. The set-point was 5.08 ± 0.04 for the former group and 4.88 ± 0.04 mg/dL for the latter, P = 0.004. Patients on Li had significantly higher Ca_i levels during citrate and Ca infusions, P = 0.0008 and 0.012, respectively; however, iPTH levels were not significantly different between the two study groups during either infusion. The shift in the iPTH set-point to the right in the Li-treated patients and the similar iPTH levels, despite higher serum Ca_i levels during both infusions, establish the presence of a clear alteration in PTH dynamics in patients on chronic Li therapy.

This article has been cited by other articles:

				A. J. Felsenfeld, M. Rodriguez, and E. Aguilera-Tejero Dynamics of Parathyroid Hormone Secretion in Health and Secondary Hyperparathyroidism Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1283 - 1305. [Abstract] [Full Text] [PDF]

				C. Livingstone and H. Rampes Lithium: a review of its metabolic adverse effects J Psychopharmacol, May 1, 2006; 20(3): 347 - 355. [Abstract] [PDF]

				P. Clement-Lacroix, M. Ai, F. Morvan, S. Roman-Roman, B. Vayssiere, C. Belleville, K. Estrera, M. L. Warman, R. Baron, and G. Rawadi Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice PNAS, November 29, 2005; 102(48): 17406 - 17411. [Abstract] [Full Text] [PDF]

				F. J. Caskey and T. M. Pickett Disturbed calcium metabolism in a patient with bipolar disorder and impaired renal function Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1752 - 1755. [Full Text] [PDF]

				G. J. Strewler A 64-Year-Old Woman With Primary Hyperparathyroidism JAMA, April 13, 2005; 293(14): 1772 - 1779. [Full Text] [PDF]

				J.-C. Souberbielle, E. Lawson-Body, B. Hammadi, E. Sarfati, A. Kahan, and C. Cormier The Use in Clinical Practice of Parathyroid Hormone Normative Values Established in Vitamin D-Sufficient Subjects J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3501 - 3504. [Abstract] [Full Text] [PDF]

				R. M.A. Hirschfeld, C. L. Bowden, M. J. Gitlin, P. E. Keck, R. H. Perlis, T. Suppes, M. E. Thase, and K. D. Wagner Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision) Focus, January 1, 2003; 1(1): 64 - 110. [Full Text] [PDF]

				E. Smith, G. A. Coetzee, and B. Frenkel Glucocorticoids Inhibit Cell Cycle Progression in Differentiating Osteoblasts via Glycogen Synthase Kinase-3beta J. Biol. Chem., May 10, 2002; 277(20): 18191 - 18197. [Abstract] [Full Text] [PDF]

				S. T. Haden, E. M. Brown, A. L. Stoll, J. Scott, and G. El-Hajj Fuleihan The Effect of Lithium on Calcium-Induced Changes in Adrenocorticotrophin Levels J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 198 - 200. [Abstract] [Full Text]

				T. W. L. Mak, C.-C. Shek, C.-C. Chow, Y.-K. Wing, and S. Lee Effects of Lithium Therapy on Bone Mineral Metabolism: A Two-Year Prospective Longitudinal Study J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3857 - 3859. [Abstract] [Full Text]